- Home
- KALU vs ARQT Comparison
KALU vs ARQT Comparison
Compare KALU & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALU
- ARQT
- Stock Information
- Founded
- KALU 1946
- ARQT 2016
- Country
- KALU United States
- ARQT United States
- Employees
- KALU N/A
- ARQT N/A
- Industry
- KALU Metal Fabrications
- ARQT Biotechnology: Pharmaceutical Preparations
- Sector
- KALU Industrials
- ARQT Health Care
- Exchange
- KALU Nasdaq
- ARQT Nasdaq
- Market Cap
- KALU 1.3B
- ARQT 1.1B
- IPO Year
- KALU 1991
- ARQT 2020
- Fundamental
- Price
- KALU $81.65
- ARQT $10.14
- Analyst Decision
- KALU Buy
- ARQT Strong Buy
- Analyst Count
- KALU 3
- ARQT 4
- Target Price
- KALU $82.33
- ARQT $15.50
- AVG Volume (30 Days)
- KALU 159.7K
- ARQT 2.2M
- Earning Date
- KALU 10-23-2024
- ARQT 11-06-2024
- Dividend Yield
- KALU 3.77%
- ARQT N/A
- EPS Growth
- KALU 252.66
- ARQT N/A
- EPS
- KALU 2.90
- ARQT N/A
- Revenue
- KALU $2,980,300,000.00
- ARQT $138,708,000.00
- Revenue This Year
- KALU N/A
- ARQT $208.32
- Revenue Next Year
- KALU $6.84
- ARQT $48.56
- P/E Ratio
- KALU $28.13
- ARQT N/A
- Revenue Growth
- KALU N/A
- ARQT 182.84
- 52 Week Low
- KALU $57.52
- ARQT $1.76
- 52 Week High
- KALU $102.42
- ARQT $13.17
- Technical
- Relative Strength Index (RSI)
- KALU 59.69
- ARQT 55.70
- Support Level
- KALU $79.07
- ARQT $8.90
- Resistance Level
- KALU $84.44
- ARQT $10.72
- Average True Range (ATR)
- KALU 2.31
- ARQT 0.70
- MACD
- KALU -0.30
- ARQT 0.05
- Stochastic Oscillator
- KALU 52.46
- ARQT 56.52
About KALU Kaiser Aluminum Corporation
Kaiser Aluminum Corp produces and sells semi-fabricated specialty aluminum products predominantly to industrial customers. Its products include fabricated aluminum mill products such as flat-rolled (plate, sheet, and coil), extruded (rod, bar, hollows, and shapes), drawn (rod, bar, pipe, tube and wire) and certain cast aluminum products. Geographically, the company generates majority of its revenue from United States.
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.